Definium Therapeutics Inc (DFTX) Stifel 2026 Virtual CNS Forum summary

Strategic overview and clinical pipeline

• Lead asset DT-120, a proprietary LSD tartrate, is in late-stage development for generalized anxiety disorder (GAD) and major depressive disorder (MDD), with pivotal data from three studies expected later this year.

• Phase II data in GAD showed significant improvements in both anxiety and depression symptoms, supporting advancement to phase III and breakthrough therapy designation for GAD.

• The company emphasizes a data-driven approach, challenging traditional assumptions in psychiatric drug development.

• Phase III programs are designed to capture broad, representative patient populations, including those with prior treatment failures.

• Durability of effect is a key focus, with primary endpoints at 6 weeks and extended observation to 12 weeks and beyond.

Clinical trial design and execution

• MDD and GAD studies are powered to detect a 5-point difference on key scales (MADRS, HAM-A), with high statistical power and sample size re-estimation to ensure robustness.

• Phase III GAD program includes two complementary studies: VOYAGE (100 mcg vs placebo) and PANORAMA (adds a 50 mcg decoy arm to address functional unblinding).

• Rigorous patient screening includes multiple independent diagnostic and severity assessments to mitigate risks from "professional patients" and ensure accurate enrollment.

• Regulatory strategy is informed by ongoing FDA dialogue, with a focus on demonstrating 12-week durability and collecting data to inform retreatment patterns.

• Functional unblinding is addressed through study design, with the company confident it will not pose regulatory issues.

Market opportunity and commercialization

• GAD and MDD represent large, underserved markets, with 10–15 million patients potentially eligible for treatment.

• The company aims for broad market impact, aspiring to reach beyond a narrow subset of patients and deliver a best-in-class therapy.

• Operational feedback from clinical sites indicates the treatment is logistically feasible, with predictable patient experiences and manageable observation periods.

• Preparations for commercialization are underway, including NDA preparation, market access planning, and KOL education.

• An investor and analyst day is scheduled for April 22 to discuss top-line data expectations and commercial strategy.